Compare FWRD & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWRD | NTLA |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 857.5M | 986.9M |
| IPO Year | 1993 | 2016 |
| Metric | FWRD | NTLA |
|---|---|---|
| Price | $28.00 | $15.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 19 |
| Target Price | ★ $35.00 | $17.32 |
| AVG Volume (30 Days) | 468.7K | ★ 5.4M |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,496,734,000.00 | $57,528,000.00 |
| Revenue This Year | $2.78 | $1.96 |
| Revenue Next Year | $4.76 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 14.54 | ★ 33.52 |
| 52 Week Low | $9.79 | $5.90 |
| 52 Week High | $35.47 | $28.25 |
| Indicator | FWRD | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 59.00 | 78.22 |
| Support Level | $26.42 | $11.34 |
| Resistance Level | $29.31 | $9.62 |
| Average True Range (ATR) | 1.11 | 1.04 |
| MACD | 0.03 | 0.57 |
| Stochastic Oscillator | 60.84 | 89.00 |
Forward Air Corp is an asset-light freight and logistics company. The company's operating segment includes Expedited Freight, Omni Logistics, and Intermodal and Corporate. The company generates maximum revenue from the Omni Logistics segment. The expedited Freight segment operates a comprehensive national network to provide expedited regional, inter-regional, and national LTL (less-than-truckload) services. It also offers customers local pick-up and delivery and other services including final mile, truckload, shipment consolidation and deconsolidation, warehousing, customs brokerage, and other handling. The Company conducts business in the United States, Canada, and Mexico.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.